Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics

Authors

Sunny Ohia Professor, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA. Sunny Ohia, Ph.D., FARVO, FAS is a Professor of Pharmacology in the College of Pharmacy and Health Sciences at Texas Southern University. Dr. Ohia has over 28 years of experience in higher education having served as a member of faculty in five universities in Canada and the United States (U.S.). He holds other academic appointments as adjunct professor of ophthalmology and visual sciences at the University of Nebraska Medical Center, Omaha and as an adjunct professor of integrative biology and pharmacology at the University of Texas Health Sciences Center in Houston. Dr. Ohia is a Fellow of the Nigerian Academy of Science and a Fellow of the Association for Research in Vision and Ophthalmology. He is the author of more than 250 original papers, book chapters, books, and abstracts and, holds three U.S. and five international Patents for his scientific work. Dr. Ohia received his Ph.D. in pharmacology from the University of Glasgow, in Scotland, United Kingdom. Dr. Ohia completed postdoctoral research training fellowships in neuroscience and in ophthalmology/visual sciences at Memorial University of Newfoundland, Canada and the University of Louisville, School of Medicine, KY, respectively. Najam Sharif Vice President, R&D Division, Santen Inc., Emeryville, CA, USA.. Najam Sharif, Ph.D., D.Sc., FARVO, FBPhS, FAOPT is a graduate of Southampton University, England where he received his BSc (Joint Honors: Biochemistry and Physiology), PhD (Neuroscience), and DSc (by thesis; Ophthalmology). He has been in the pharmaceutical industry for >34-years holding leadership positions of increasing scope and responsibility at Parke-Davis/Warner-Lambert (Pfizer), Syntex Research (Roche), Alcon-Novartis, and is currently at Santen Inc (Vice President, Global Alliances and External Research, Ophthalmology Innovation Center, R&D Division). He contributed to the discovery/development and US FDA approvals of multiple drugs to treat glaucoma/ocular hypertension and ocular allergies. He was recently elected as a Gold Fellow of ARVO, Fellow of British Pharmacological Society (BPS), and a Trustee of Assoc. Ocular Pharmacology & Therapeutics. He was the recipient of the inaugural Dr. Roger Vogel award for pharmaceutical research presented by the ARVO Foundation (2014), the "Sir James Black Award� for contributions to drug discovery from BPS (2017), and the awardee of the Ernst H Barany Prize for exemplary contributions to ocular pharmacology (2020). He was also elected to the Board of Directors and the Scientific Advisory Board of The Glaucoma Foundation (2020). He serves on the editorial boards of numerous scientific journals, and is an Adjunct Professor and Thesis advisor at several global universities.